The investigational chemoimmunotherapy antibody-drug conjugate demonstrated enhanced tumor inhibition in preclinical models.
|Articles|August 6, 2013
Targeted Therapies in Oncology
- July 2013
- Volume 2
- Issue 4
ASCO Quick Reference Chart
Author(s)Anna Azvolinsky, PhD
A quick reference chart of the key clinical trials presented at the American Society of Clinical Oncology (ASCO) 2013 Annual Meeting.
Advertisement
Articles in this issue
about 13 years ago
NCCN Guidelines Updates: Solid Tumorsabout 13 years ago
Targeted Advances in Melanomaabout 13 years ago
NCCN Guidelines Updates: Hematologic Malignanciesabout 13 years ago
Exploring the Potential for Expansion of Anti-HER2 Therapyabout 13 years ago
The Changing Landscape of Oncology: Impact for Payers and Providersabout 13 years ago
Positive Findings for Nab-Paclitaxel/Gemcitabine Combinationabout 13 years ago
Changing Landscape for Genetic Testingabout 13 years ago
Ibrutinib/R-CHOP Combination Achieves 100% Response Rate in NHLabout 13 years ago
Ganetespib-Docetaxel Combination Improves SurvivalAdvertisement
Related to this article
Updated ARC-20 data show casdatifan delivers durable responses and strong survival in clear cell renal cell carcinoma, alone and in key first-line combinations.
Rural breast cancer deaths rise faster than urban rates, driven by low income, later diagnosis, and treatment gaps—warning of widening disparities by 2035.
The TASKIN trial found a 12-month overall survival rate of 61.3% with vilamakitug plus standard-of-care therapy, with exploratory findings suggesting potential benefit in right-sided tumors.
Lyudmila Bazhenova, MD, discusses the FDA’s expanded approval of taletrectinib for ROS1-positive non–small cell lung cancer.
UGN-103, a formulation of intravesical mitomycin as treatment for low-grade intermediate-risk non–muscle-invasive bladder cancer, will receive FDA review with a PDUFA date of June 14, 2027.
FDA approves dostarlimab for MSI-H/dMMR locally advanced rectal cancer, driving high complete responses and helping many patients avoid surgery, radiation, and chemo.
SABR improved recurrence-free survival vs historical benchmark with IVC tumor thrombus; investigators hypothesize this could be used to reduce invasive surgery.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
3
Upfront Surgery Vs Total Neoadjuvant Therapy in Rectal Cancer
4
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
5